Apothecary Pharma Recalls Compounded Injections Nationwide

Apothecary Pharma is recalling compounded tirzepatide and a vial of NAD injection distributed nationwide because the sterility of the products cannot be assured, according to the U.S. Food and Drug Administration. The FDA classified the recall as Class II on October 8, indicating that serious health consequences are considered unlikely. The agency’s recall record lists the action as ongoing. The recall covers 22 lots of compounded tirzepatide injection, supplied in 4-milliliter multidose vials at a concentration of 18 milligrams per milliliter. The affected lot numbers are AP202622 through AP202625 and AP202627 through AP202644; AP202626 is not listed. The products’ beyond-use dates range from October 7 to November 26, 2026. The recall also includes one lot of Apothecary NAD Injection, AP202647, in a 6-milliliter multidose vial. Its beyond-use date is October 13, 2026. Apothecary Pharma initiated the voluntary recall on September 24 and notified recipients by letter, according to the FDA record. The agency’s classification describes a recall in which exposure may cause temporary or medically reversible health effects, while the likelihood of serious harm is considered remote....